{"id":"kamrab-hrig","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Anaphylaxis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HRIG contains human antibodies specific to rabies virus antigens, particularly the glycoprotein. When administered post-exposure, these antibodies neutralize rabies virus and prevent it from reaching the central nervous system. This passive immunization is used in conjunction with rabies vaccine to provide immediate protection while the body mounts its own immune response.","oneSentence":"KamRAB is a human rabies immunoglobulin (HRIG) that provides passive immunity by supplying antibodies against rabies virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:06.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-exposure prophylaxis of rabies in non-vaccinated or incompletely vaccinated individuals"}]},"trialDetails":[{"nctId":"NCT02040090","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Kamada, Ltd.","startDate":"2013-04","conditions":"Rabies","enrollment":118},{"nctId":"NCT02912845","phase":"PHASE3","title":"Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies","status":"COMPLETED","sponsor":"Kamada, Ltd.","startDate":"2016-08-01","conditions":"Rabies","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KamRAB - HRIG","genericName":"KamRAB - HRIG","companyName":"Kamada, Ltd.","companyId":"kamada-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KamRAB is a human rabies immunoglobulin (HRIG) that provides passive immunity by supplying antibodies against rabies virus. Used for Post-exposure prophylaxis of rabies in non-vaccinated or incompletely vaccinated individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}